Italia markets open in 8 hours 17 minutes

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
3,0700-0,2300 (-6,97%)
Alla chiusura: 06:50PM GMT

OPKO Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100

Impiegati a tempo pieno5.269

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Phillip Frost Ph.D.Chairman & CEO971,2kN/D1936
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.Vice Chairman & Chief Technical Officer911,2kN/D1947
Mr. Adam E. LogalSr. VP & CFO1,11MN/D1978
Mr. Steven D. RubinExec. VP of Admin. & Director821,2kN/D1960
Dr. Jon R. CohenSr. VP & Director1,74MN/D1955
Dr. Arie GutmanPres of APIN/DN/D1954
Mr. James DeMarcoSr. VP of Pharmaceutical SalesN/DN/DN/D
Dr. Akhtar AshfaqSr. VP of Clinical R&D and Medical AffairsN/DN/DN/D
Ms. Jane Pine Wood Esq., J.D.Chief Legal Officer of Bio-Reference LaboratoriesN/DN/D1963
Dr. David Okrongly Ph.D.Pres of OPKO DiagnosticsN/DN/D1959
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Governance aziendale

L'ISS Governance QualityScore di OPKO Health, Inc. al 26 settembre 2021 è 6. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 9; diritti degli azionisti: 3; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.